Cuban Vaccine for Advanced Lung Cancer Extended to Primary Health Care. HAVANA, CUBA.- The first Cuban therapeutic vaccine to treat advanced lung cancer, the only one registered in the world for this type of malignant tumor, has been extended primary health care in the country. With the name CIMAVAX EGF, the product, developed by Havana’s Center for Molecular Immunology, is of proven effectiveness and increases the survival of patients with this disease.">Cuban Vaccine for Advanced Lung Cancer Extended to Primary Health Care. HAVANA, CUBA.- The first Cuban therapeutic vaccine to treat advanced lung cancer, the only one registered in the world for this type of malignant tumor, has been extended primary health care in the country. With the name CIMAVAX EGF, the product, developed by Havana’s Center for Molecular Immunology, is of proven effectiveness and increases the survival of patients with this disease.">

Cuba Headlines

Cuba News, Breaking News, Articles and Daily Information

Cuban Vaccine for Advanced Lung Cancer Extended to Primary Health Care

  • Submitted by: manso
  • 12 / 17 / 2010

2010.12.16 - 13:30:58 / [email protected]. Cuban Vaccine for Advanced Lung Cancer Extended to Primary Health Care. HAVANA, CUBA.- The first Cuban therapeutic vaccine to treat advanced lung cancer, the only one registered in the world for this type of malignant tumor, has been extended primary health care in the country.  

With the name CIMAVAX EGF, the product, developed by Havana’s Center for Molecular Immunology, is of proven effectiveness and increases the survival of patients with this disease, according to information provided to ACN by Pedro Pablo Guerra, of the National Coordination Center for Clinical Trials

The researcher announced that the immunogen is being extended by way of a stage four clinical trial protocol, which includes people with advanced lung cancer in stages three and four who had no response to specific oncological treatment and are receiving palliative care in their health areas.

This clinical trial, which began in June 2009 in Bayamo, eastern Granma province, is being extended throughout the country in the polyclinics, and specifically measures safety and effectiveness by way of the study of adverse effects and variables, such as survival, quality of life and nutritional state.

This is the first time that a clinical trial is carried out in Primary Health Care and there are currently about a hundred patients in the trial, who will receive the drug as their health permits, the specialist underlined.

He pointed out that this is part of the objectives of the Ministry of Public Health in bringing products to primary care, adding that for 2011, the institution has among its projects the inclusion of another group of patients.

He stressed that currently there is a phase three clinical trial of the vaccine, which is carried out in hospitals and should include some 500 patients, a study that will give the definitive registration of the product, recognized in various countries.

The National Coordination Center for Clinical Trials, with nearly 20 years of experience, is currently working on over 60 clinical trials for indications in breast, lung and prostate cancers; it also has projects related to AIDS, in conjunction with Havana’s Center for Molecular Immunology.

The streptokinase study for hemorrhoids was recently concluded, along with Havana’s Center for Genetic Engineering and Biotechnology, and it’s also carrying out laboratory research works on agriculture, among others.

The performance of more clinical trials according to international standards is among the challenges of the institution.

These scientific results were presented at the 4th Congress of Pharmacology, which ends on Friday in this capital, attended by over 400 delegates from 35 countries.

Source: ACN

Related News

Comments